Sugi Predict

Sugi Predict / Targets / CNKSR1

CNKSR1

Connector enhancer of kinase suppressor of ras 1 · Q969H4 · CNKSR1 on Sugi Atlas →

1,412 patent compounds predicted against CNKSR1, 753 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15811518 SCHEMBL15811518 1.00 14/20
SCHEMBL18160894 SCHEMBL18160894 0.80 14/20
SCHEMBL17211669 SCHEMBL17211669 0.78 14/20
SCHEMBL17211653 SCHEMBL17211653 0.73 14/20
SCHEMBL19867224 SCHEMBL19867224 0.66 14/20
SCHEMBL17213426 SCHEMBL17213426 0.65 14/20
SCHEMBL19867321 SCHEMBL19867321 0.64 14/20
SCHEMBL18148035 SCHEMBL18148035 0.51 14/20
SCHEMBL18148038 SCHEMBL18148038 0.51 14/20
SCHEMBL15811509 SCHEMBL15811509 1.00 13/20
SCHEMBL17200816 SCHEMBL17200816 1.00 13/20
SCHEMBL17211656 SCHEMBL17211656 1.00 13/20
SCHEMBL18148025 SCHEMBL18148025 1.00 13/20
SCHEMBL18160877 SCHEMBL18160877 1.00 13/20
SCHEMBL18163741 SCHEMBL18163741 1.00 13/20
SCHEMBL18163743 SCHEMBL18163743 1.00 13/20
SCHEMBL18163744 SCHEMBL18163744 1.00 13/20
SCHEMBL18163762 SCHEMBL18163762 0.85 13/20
SCHEMBL18163763 SCHEMBL18163763 0.83 13/20
SCHEMBL18163747 SCHEMBL18163747 0.82 13/20

Clinical trials — most relevant to CNKSR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From Real World PHASE4UNKNOWN
Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis PHASE4UNKNOWN
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis PHASE3ACTIVE_NOT_RECRUITING
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
FITMI - First In Treating Male Infertility PHASE2ACTIVE_NOT_RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE PHASE1RECRUITING
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Genetics of Rheumatoid Arthritis nanCOMPLETED
Genetic Registry for Rheumatoid Arthritis nanCOMPLETED
CTHRC1: A Biomarker for Evaluation of Rheumatoid Arthritis Disease Activity nanUNKNOWN
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis nanCOMPLETED
Identification of Genomic Biomarkers for Rheumatoid Arthritis With Late Onset nanWITHDRAWN
Genetics and Mechanisms of Rheumatoid Arthritis nanCOMPLETED
People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT) nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
CTHRC1 Abiomarker in Rheumatoid Arthritis Diagnosis nanUNKNOWN
Role of CTHRC1 in Diagnosis of Rheumatoid Arthritis nanUNKNOWN
CXCL10 As a Biomarker Of ILD in Patients WithRA nanUNKNOWN
Adenosylmethionine Metabolism in Human Inflammation nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CNKSR1 binder may also engage these)

ProteinNameSimilarity
A1L3T7 — 0.993 A1L3T7 →
Q8C6B2 — 0.993 Q8C6B2 →
Q96MK2 — 0.990 Q96MK2 →
Q8TE68 — 0.990 Q8TE68 →
Q8WWN8 — 0.989 Q8WWN8 →
Q9Z1I6 — 0.989 Q9Z1I6 →
Q66H85 — 0.989 Q66H85 →
Q5VV41 — 0.989 Q5VV41 →
A7E3N7 — 0.988 A7E3N7 →
Q9P107 — 0.988 Q9P107 →
Q6PGG2 — 0.987 Q6PGG2 →
Q61210 — 0.987 Q61210 →
Q1JQC5 — 0.987 Q1JQC5 →
Q9H8Y5 — 0.987 Q9H8Y5 →
Q9BRR9 — 0.987 Q9BRR9 →
ARHGEF1 Rho guanine nucleotide exchange factor 1 0.987 landscape →
CDC42BPG Serine/threonine-protein kinase MRCK gamma 0.986 landscape →
Q3KR16 — 0.986 Q3KR16 →
Q8VDP3 — 0.985 Q8VDP3 →
Q400G9 — 0.985 Q400G9 →
Q61193 — 0.985 Q61193 →
Q58CQ5 — 0.984 Q58CQ5 →
O75064 — 0.984 O75064 →
Q6KAU8 — 0.984 Q6KAU8 →
A2AB59 — 0.983 A2AB59 →
P70218 — 0.983 P70218 →
Q7Z3H0 — 0.983 Q7Z3H0 →
D3ZBP4 — 0.983 D3ZBP4 →
O15211 — 0.983 O15211 →
Q9UQQ2 — 0.982 Q9UQQ2 →